{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:05:49Z","timestamp":1792123549072,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Health Research Project","award":["TJWJ2024QN040"],"award-info":[{"award-number":["TJWJ2024QN040"]}]},{"name":"the major special project on public health science and technology in Tianjin","award":["24ZXGZSY00120"],"award-info":[{"award-number":["24ZXGZSY00120"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-056B"],"award-info":[{"award-number":["TJYXZDXK-056B"]}]},{"name":"the Science and Technology Project of Tianjin Municipal Health Committee","award":["TJWJ2022XK018"],"award-info":[{"award-number":["TJWJ2022XK018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01860-3","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:00:08Z","timestamp":1761368408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel fourth generation of CAR-T cells: CD19 CAR-T cells engineered to express membrane-bound interleukin-15 and CXCR5 for the treatment of lymphoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Xinping","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jile","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5995-7558","authenticated-orcid":false,"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"3","key":"1860_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3324\/haematol.2022.280678","volume":"108","author":"AS Wayne","year":"2023","unstructured":"Wayne AS, Huynh V, Hijiya N, et al. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2023;108(3):747\u201360.","journal-title":"Haematologica"},{"issue":"1","key":"1860_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/bjh.19057","volume":"204","author":"A Dodero","year":"2024","unstructured":"Dodero A, Bramanti S, Di Trani M, et al. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas. Br J Haematol. 2024;204(1):151\u20139.","journal-title":"Br J Haematol"},{"issue":"5","key":"1860_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024;143(5):404\u201316.","journal-title":"Blood"},{"issue":"3","key":"1860_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2023.283162","volume":"109","author":"LI Gordon","year":"2024","unstructured":"Gordon LI, Liu FF, Braverman J, et al. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 2024;109(3):857\u201366.","journal-title":"Haematologica"},{"issue":"10402","key":"1860_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet. 2023;402(10402):641\u201354.","journal-title":"Lancet"},{"issue":"10","key":"1860_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295\u2013312.","journal-title":"Am J Hematol"},{"key":"1860_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221141511","volume":"13","author":"O Albanyan","year":"2022","unstructured":"Albanyan O, Chavez J, Munoz J. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Ther Adv Hematol. 2022;13:20406207221141511.","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"1860_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","volume":"29","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann MS, Hunter BD, Cobb PW, et al. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma. Transplant Cell Ther. 2023;29(7):440\u20138.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"1860_CR9","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1038\/s41598-022-16616-2","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Li Q, Yan ZX, et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci Rep. 2022;12(1):12506. https:\/\/doi.org\/10.1038\/s41598-022-16616-2.","journal-title":"Sci Rep"},{"key":"1860_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121341","volume":"281","author":"Y Luo","year":"2022","unstructured":"Luo Y, Chen Z, Sun M, et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy. Biomaterials. 2022;281:121341. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121341.","journal-title":"Biomaterials"},{"issue":"1","key":"1860_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/10815589241291846","volume":"73","author":"K Han","year":"2025","unstructured":"Han K, Wang X, Chen G, et al. Targeted therapy of multiple myeloma by IL21-NKG2D CAR-T cells. J Investig Med. 2025;73(1):45\u201353. https:\/\/doi.org\/10.1177\/10815589241291846.","journal-title":"J Investig Med"},{"key":"1860_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958960","volume":"13","author":"JF Hu","year":"2022","unstructured":"Hu JF, Wang ZW, Liao CY, et al. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability. Front Immunol. 2022;13:958960. https:\/\/doi.org\/10.3389\/fimmu.2022.958960. (2022 Aug 5.).","journal-title":"Front Immunol"},{"issue":"1","key":"1860_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-023-00625-0","volume":"10","author":"W Lei","year":"2024","unstructured":"Lei W, Zhao A, Liu H, et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discov. 2024;10(1):5. https:\/\/doi.org\/10.1038\/s41421-023-00625-0.","journal-title":"Cell Discov"},{"issue":"4","key":"1860_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121(4):573\u201384.","journal-title":"Blood"},{"issue":"3","key":"1860_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","volume":"117","author":"CS Hinrichs","year":"2011","unstructured":"Hinrichs CS, Borman ZA, Gattinoni L, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117(3):808\u201314.","journal-title":"Blood"},{"issue":"2","key":"1860_CR16","first-page":"594","volume":"123","author":"E Lugli","year":"2013","unstructured":"Lugli E, Dominguez MH, Gattinoni L, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013;123(2):594\u20139.","journal-title":"J Clin Invest"},{"key":"1860_CR17","doi-asserted-by":"publisher","first-page":"1235711","DOI":"10.3389\/fonc.2023.1235711","volume":"13","author":"M Yadav","year":"2023","unstructured":"Yadav M, Uikey BN, Rathore SS, et al. Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment. Front Oncol. 2023;13:1235711.","journal-title":"Front Oncol"},{"issue":"1","key":"1860_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/acs.jproteome.6b00233","volume":"16","author":"N Osinalde","year":"2017","unstructured":"Osinalde N, Sanchez-Quiles V, Akimov V, et al. Characterization of receptor-associated protein complex assembly in interleukin (IL)-2- and IL-15-activated T-cell lines. J Proteome Res. 2017;16(1):106\u201321.","journal-title":"J Proteome Res"},{"issue":"2","key":"1860_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood-2005-12-4827","volume":"108","author":"GH Cornish","year":"2006","unstructured":"Cornish GH, Sinclair LV, Cantrell DA. Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006;108(2):600\u20138.","journal-title":"Blood"},{"issue":"22","key":"1860_CR20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1860_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","volume":"22","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhou N, Zhou L, et al. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol. 2021;22(3):358\u201369.","journal-title":"Nat Immunol"},{"issue":"12","key":"1860_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1237327","volume":"5","author":"J Weng","year":"2016","unstructured":"Weng J, Moriarty KE, Baio FE, et al. IL-15 enhances the antitumor effect of human antigen-specific CD8(+) T cells by cellular senescence delay. Oncoimmunology. 2016;5(12):e1237327.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1860_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4049\/jimmunol.0803355","volume":"184","author":"MM Sandau","year":"2010","unstructured":"Sandau MM, Kohlmeier JE, Woodland DL, et al. IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool. J Immunol. 2010;184(1):35\u201344.","journal-title":"J Immunol"},{"issue":"24","key":"1860_CR24","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20139.","journal-title":"Blood"},{"issue":"2","key":"1860_CR25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1073\/pnas.0610115104","volume":"104","author":"N Sato","year":"2007","unstructured":"Sato N, Patel HJ, Waldmann TA, et al. The IL-15\/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A. 2007;104(2):588\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"1860_CR26","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113(48):E7788\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1860_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"key":"1860_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020.","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"1860_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188799","volume":"1877","author":"B Wang","year":"2022","unstructured":"Wang B, Wang M, Ao D, et al. CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(5):188799.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"1860_CR30","doi-asserted-by":"publisher","first-page":"15745","DOI":"10.1038\/s41598-025-99017-5","volume":"15","author":"M Qin","year":"2025","unstructured":"Qin M, Li X, Gong X, Hu Y, Tang M. Integrative bioinformatics and machine learning identify key crosstalk genes and immune interactions in head and neck cancer and Hodgkin lymphoma. Sci Rep. 2025;15(1):15745. https:\/\/doi.org\/10.1038\/s41598-025-99017-5.","journal-title":"Sci Rep"},{"issue":"4","key":"1860_CR31","first-page":"305","volume":"41","author":"LH Tan","year":"2009","unstructured":"Tan LH. A practical approach to the understanding and diagnosis of lymphoma: an assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles. Pathology. 2009;41(4):305\u201326.","journal-title":"Pathology"},{"issue":"9","key":"1860_CR32","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1080\/10428194.2021.1913150","volume":"62","author":"RK Ollikainen","year":"2021","unstructured":"Ollikainen RK, Kotkaranta PH, Kemppainen J, Teppo HR, Kuitunen H, Pirinen R, et al. Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;62(9):2151\u201360. https:\/\/doi.org\/10.1080\/10428194.2021.1913150.","journal-title":"Leuk Lymphoma"},{"key":"1860_CR33","first-page":"507","volume":"22","author":"G Li","year":"2021","unstructured":"Li G, Guo J, Zheng Y, et al. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells. Mol Ther. 2021;22:507\u201317.","journal-title":"Mol Ther"},{"issue":"20","key":"1860_CR34","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-06-721662","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-06-721662.","journal-title":"Blood"},{"issue":"18","key":"1860_CR35","doi-asserted-by":"publisher","first-page":"18568","DOI":"10.1002\/cam4.6463","volume":"12","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu D, Zhang X, Zhang M, Li S, Feng X, et al. MYC overexpression but not MYC\/BCL2 double expression predicts survival in bulky mass diffuse large B-cell lymphoma patients. Cancer Med. 2023;12(18):18568\u201377. https:\/\/doi.org\/10.1002\/cam4.6463.","journal-title":"Cancer Med"},{"issue":"2","key":"1860_CR36","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S2352-3026(23)00345-9","volume":"11","author":"P Abrisqueta","year":"2024","unstructured":"Abrisqueta P, Gonz\u00e1lez-Barca E, Panizo C, et al. Polatuzumab vedotin plu8s rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study. Lancet Haematol. 2024;11(2):e136\u201346. https:\/\/doi.org\/10.1016\/S2352-3026(23)00345-9.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1860_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart CM, Siegler EL, Sakemura RL, et al. IL-4 drives exhaustion of CD8+ CART cells. Nat Commun. 2024;15(1):7921. https:\/\/doi.org\/10.1038\/s41467-024-51978-3.","journal-title":"Nat Commun"},{"key":"1860_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1601808","volume":"15","author":"H Du","year":"2025","unstructured":"Du H, Wang J, Wang Z. Cardiovascular adverse effects of immunotherapy in cancer: insights and implications. Front Oncol. 2025;15:1601808. https:\/\/doi.org\/10.3389\/fonc.2025.1601808. (2025 Jun 18).","journal-title":"Front Oncol"},{"issue":"24","key":"1860_CR39","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow K, Roberto A, Roederer M, et al. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res. 2015;75(24):5187\u201393.","journal-title":"Cancer Res"},{"key":"1860_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165404","volume":"14","author":"H Shi","year":"2023","unstructured":"Shi H, Li A, Dai Z, et al. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models. Front Immunol. 2023;14:1165404.","journal-title":"Front Immunol"},{"issue":"1","key":"1860_CR41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-022-03626-x","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhuang Q, Wang F, et al. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J Transl Med. 2022;20(1):432.","journal-title":"J Transl Med"},{"issue":"1","key":"1860_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.14336\/AD.2019.0416","volume":"11","author":"A Jahn","year":"2020","unstructured":"Jahn A, Scherer B, Fritz G, et al. Statins induce a DAF-16\/Foxo-dependent longevity phenotype via JNK-1 through mevalonate depletion in C. elegans. Aging Dis. 2020;11(1):60\u201372.","journal-title":"Aging Dis"},{"key":"1860_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.imlet.2017.08.010","volume":"190","author":"TO Robinson","year":"2017","unstructured":"Robinson TO, Schluns KS. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. 2017;190:159\u201368.","journal-title":"Immunol Lett"},{"issue":"1","key":"1860_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10(1):24.","journal-title":"Biomark Res"},{"issue":"23","key":"1860_CR45","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.1182\/bloodadvances.2023010158","volume":"7","author":"I Spasevska","year":"2023","unstructured":"Spasevska I, Sharma A, Steen CB, et al. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Adv. 2023;7(23):7216\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2023010158.","journal-title":"Blood Adv"},{"issue":"1","key":"1860_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3324\/haematol.2017.177162","volume":"103","author":"M Rudelius","year":"2018","unstructured":"Rudelius M, Rosenfeldt MT, Leich E, et al. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. Haematologica. 2018;103(1):116\u201325. https:\/\/doi.org\/10.3324\/haematol.2017.177162.","journal-title":"Haematologica"},{"key":"1860_CR47","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R, et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma. Front Oncol. 2019;9:767.","journal-title":"Front Oncol"},{"issue":"13","key":"1860_CR48","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4(13):2871\u201383.","journal-title":"Blood Adv"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01860-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:55Z","timestamp":1764917335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01860-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1860"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01860-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as potential conflicts of interest. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved by the Ethics Committee of Tianjin First Central Hospital. Our study complies with the Declaration of Helsinki. All patients signed informed consent forms. All animal experiments and procedures were approved by the Ethics Committee of Tianjin First Central Hospital. We confirmed that the tumor burden did not exceed the recommended dimensions and that the animals were anesthetized and killed using acceptable methods. The mice were euthanized using cervical dislocation. The death of the experimental animals was determined by paying attention to their respiration, pupils, and neural responses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"325"}}